PeerVoice Symposium

Jean-Jacques Kiladjian is Professor of Medicine at Université Paris Cité, head of the Clinical Research department of the French National Institute of Health and Medical Research (Inserm), consultant Hematologist and head of the Clinical Investigation Center of the Saint-Louis Hospital, Paris, France. Since 2025, he is also at the head of the clinical research department of the National Institute of Health and Medical Research (INSERM).

Prof. Kiladjian’s research has centered on Myeloproliferative neoplasms and Myelodysplastic syndromes. In these disorders, he has been very active in evaluating novel therapeutics and implementing clinical trials. He is published in many peer-reviewed journals including The New England Journal of Medicine, Journal of Clinical Oncology, Blood, Lancet Haematology, HemaSphere, Leukemia, etc., and has authored several book chapters. He is associate Editor of Leukemia, European Journal of Haematology and HemaSphere. He is an active member of many societies including the European Hematology Association (EHA), the American Society of Hematology (ASH), the European LeukemiaNet (ELN), the European School of Hematology (ESH). Prof. Kiladjian was elected President of the French Intergroup of Myeloproliferative disorders (FIM) since 2008. He has provided educational lectures in several French and international meetings over the years, including at the ASH, the EHA, and the American Society of Clinical Oncology (ASCO) annual meetings.